RESUMO
Pulmonary arterial hypertension (PAH) is a devastating pulmonary circulation disease lacking high-efficiency therapeutics. The present study aims to decipher the therapeutic mechanism of Rhodiola crenulata, a well-known traditional chinese medicine with cardiopulmonary protection capacity, on PAH by exploiting functional lipidomics. The rat model with PAH was successfully established for first, following Rhodiola crenulata water extract (RCE) treatment, then analysis of chemical constituents of RCE was performed, additional morphologic, hemodynamic, echocardiographic measurements were examined, further targeted lipidomics assay was performed to identify differential lipidomes, at last accordingly mechanism assay was done by combining qRT-PCR, Western blot and ELISA. Differential lipidomes were identified and characterized to differentiate the rats with PAH from healthy controls, mostly assigned to acylcarnitines, phosphatidylcholines, sphingomyelin associated with the PAH development. Excitingly, RCE administration reversed high level of decadienyl-L-carnitine by the modulation of metabolic enzyme CPT1A in mRNA and protein level in serum and lung in the rats with PAH. Furthermore, RCE was observed to reduce autophagy, confirmed by significantly inhibited PPARγ, LC3B, ATG7 and upregulated p62, and inactivated LKB1-AMPK signal pathway. Notably, we accurately identified the constituents in RCE, and delineated the therapeutic mechansim that RCE ameliorated PAH through inhibition of fatty acid oxidation and autophagy. Altogether, RCE might be a potential therapeutic medicine with multi-targets characteristics to prevent the progression of PAH. This novel findings pave a critical foundation for the use of RCE in the treatment of PAH.
Assuntos
Carnitina/análogos & derivados , Ácidos Graxos/metabolismo , Extratos Vegetais/farmacologia , Hipertensão Arterial Pulmonar , Rhodiola , Animais , Autofagia , Carnitina/antagonistas & inibidores , Metabolismo dos Lipídeos/efeitos dos fármacos , Hipertensão Arterial Pulmonar/tratamento farmacológico , Ratos , Rhodiola/químicaRESUMO
Dysregulation of the tryptophan (Trp)-NAD+ pathway has been related to several pathological conditions, and the metabolites in this pathway are known to influence mitochondrial respiration and redox status. The aim of this project was to investigate if stimulation of beta-oxidation and mitochondrial proliferation by the mitochondrial-targeted compound 2-(tridec-12-yn-1-ylthio)acetic acid (1-triple TTA) would influence metabolites of the Trp-Kyn-NAD+ pathway. We wished to investigate how carnitine depletion by meldonium-treatment influenced these metabolites. After dietary treatment of male Wistar rats with 1-triple TTA for three weeks, increased hepatic mitochondrial- and peroxisomal fatty acid oxidation resulted. The plasma content of total carnitines decreased compared to control animals, whereas hepatic genes involved in CoA biosynthesis were upregulated by 1-triple TTA treatment. The plasma Trp level and individual metabolites in the kynurenine pathway were increased by 1-triple TTA, associated with decreased hepatic gene expression of indoleamine2,3-dioxygenase. 1-triple TTA treatment increased conversion of Trp to nicotinamide (Nam) as the plasma content of quinolinic acid, Nam and N1-methylnicotinamide (mNam) increased, accompanied with suppression of hepatic gene expression of α-amino-α-carboxymuconate-ε-semialdehyde decarboxylase. A positive correlation between mitochondrial fatty acid oxidation and Trp-derivatives was found. Almost identical results were obtained by 1-triple TTA in the presence of meldonium, which alone exerted minor effects. Moreover, the plasma Kyn:Trp ratio (KTR) correlated negatively to mitochondrial function. Whether increased flux through the Trp-NAD+ pathway increased redox status and lowered inflammation locally and systemically should be considered.
Assuntos
Cinurenina/metabolismo , Fígado/metabolismo , Mitocôndrias/metabolismo , Niacinamida/metabolismo , Triptofano/metabolismo , Animais , Carnitina/antagonistas & inibidores , Proliferação de Células/efeitos dos fármacos , Cinurenina/sangue , Metabolismo dos Lipídeos/efeitos dos fármacos , Fígado/citologia , Fígado/efeitos dos fármacos , Masculino , Redes e Vias Metabólicas/efeitos dos fármacos , Metilidrazinas/farmacologia , Mitocôndrias/efeitos dos fármacos , NAD/metabolismo , Niacinamida/sangue , Oxirredução/efeitos dos fármacos , Peroxissomos/efeitos dos fármacos , Peroxissomos/metabolismo , Ratos , Triptofano/sangueRESUMO
Mutations in the gene that encodes the principal l-carnitine transporter, OCTN2, can lead to a reduced intracellular l-carnitine pool and the disease Primary Carnitine Deficiency. l-Carnitine supplementation is used therapeutically to increase intracellular l-carnitine. As AMPK and insulin regulate fat metabolism and substrate uptake, we hypothesized that AMPK-activating compounds and insulin would increase l-carnitine uptake in C2C12 myotubes. The cells express all three OCTN transporters at the mRNA level, and immunohistochemistry confirmed expression at the protein level. Contrary to our hypothesis, despite significant activation of PKB and 2DG uptake, insulin did not increase l-carnitine uptake at 100 nM. However, l-carnitine uptake was modestly increased at a dose of 150 nM insulin. A range of AMPK activators that increase intracellular calcium content [caffeine (10 mM, 5 mM, 1 mM, 0.5 mM), A23187 (10 µM)], inhibit mitochondrial function [sodium azide (75 µM), rotenone (1 µM), berberine (100 µM), DNP (500 µM)], or directly activate AMPK [AICAR (250 µM)] were assessed for their ability to regulate l-carnitine uptake. All compounds tested significantly inhibited l-carnitine uptake. Inhibition by caffeine was not dantrolene (10 µM) sensitive despite dantrolene inhibiting caffeine-mediated calcium release. Saturation curve analysis suggested that caffeine did not competitively inhibit l-carnitine transport. To assess the potential role of AMPK in this process, we assessed the ability of the AMPK inhibitor Compound C (10 µM) to rescue the effect of caffeine. Compound C offered a partial rescue of l-carnitine uptake with 0.5 mM caffeine, suggesting that AMPK may play a role in the inhibitory effects of caffeine. However, caffeine likely inhibits l-carnitine uptake by alternative mechanisms independently of calcium release. PKA activation or direct interference with transporter function may play a role.
Assuntos
Carnitina/antagonistas & inibidores , Ativadores de Enzimas/farmacologia , Mioblastos/efeitos dos fármacos , Proteínas de Transporte de Cátions Orgânicos/metabolismo , Proteínas Quinases Ativadas por AMP/genética , Proteínas Quinases Ativadas por AMP/metabolismo , Aminoimidazol Carboxamida/análogos & derivados , Aminoimidazol Carboxamida/farmacologia , Animais , Berberina/farmacologia , Transporte Biológico/efeitos dos fármacos , Cafeína/farmacologia , Calcimicina/farmacologia , Cálcio/metabolismo , Carnitina/metabolismo , Linhagem Celular , Dantroleno/farmacologia , Ativação Enzimática/efeitos dos fármacos , Expressão Gênica , Insulina/farmacologia , Camundongos , Mioblastos/citologia , Mioblastos/enzimologia , Proteínas de Transporte de Cátions Orgânicos/genética , Isoformas de Proteínas/agonistas , Isoformas de Proteínas/genética , Isoformas de Proteínas/metabolismo , Ribonucleotídeos/farmacologia , Rotenona/farmacologia , Azida Sódica/farmacologia , Membro 5 da Família 22 de Carreadores de SolutoRESUMO
The consequences of carnitine depletion upon metabolic and contractile characteristics of skeletal muscle remain largely unexplored. Therefore, we investigated the effect of N-trimethyl-hydrazine-3-propionate (THP) administration, a carnitine analog inhibiting carnitine biosynthesis and renal reabsorption of carnitine, on skeletal muscle function and energy metabolism. Male Sprague-Dawley rats were fed a standard rat chow in the absence (CON; n = 8) or presence of THP (n = 8) for 3 wk. Following treatment, rats were fasted for 24 h prior to excision of their soleus and EDL muscles for biochemical characterization at rest and following 5 min of contraction in vitro. THP treatment reduced the carnitine pool by â¼80% in both soleus and EDL muscles compared with CON. Carnitine depletion was associated with a 30% decrease soleus muscle weight, whereas contractile function (expressed per gram of muscle), free coenzyme A, and water content remained unaltered from CON. Muscle fiber distribution and fiber area remained unaffected, whereas markers of apoptosis were increased in soleus muscle of THP-treated rats. In EDL muscle, carnitine depletion was associated with reduced free coenzyme A availability (-25%, P < 0.05), impaired peak tension development (-44%, P < 0.05), and increased glycogen hydrolysis (52%, P < 0.05) during muscle contraction, whereas PDC activation, muscle weight, and water content remained unaltered from CON. In conclusion, myopathy associated with carnitine deficiency can have different causes. Although muscle atrophy, most likely due to increased apoptosis, is predominant in muscle composed predominantly of type I fibers (soleus), disturbance of energy metabolism appears to be the major cause in muscle composed of type II fibers (EDL).
Assuntos
Carnitina/deficiência , Deficiências Nutricionais/fisiopatologia , Modelos Animais de Doenças , Metabolismo Energético , Contração Muscular , Músculo Esquelético/fisiopatologia , Atrofia Muscular/etiologia , Animais , Apoptose , Biomarcadores/metabolismo , Carnitina/antagonistas & inibidores , Deficiências Nutricionais/induzido quimicamente , Deficiências Nutricionais/metabolismo , Deficiências Nutricionais/patologia , Glicogenólise , Masculino , Metilidrazinas , Desenvolvimento Muscular , Fibras Musculares de Contração Rápida/metabolismo , Fibras Musculares de Contração Rápida/patologia , Fibras Musculares de Contração Lenta/metabolismo , Fibras Musculares de Contração Lenta/patologia , Músculo Esquelético/metabolismo , Músculo Esquelético/patologia , Distribuição Aleatória , Ratos Sprague-DawleyRESUMO
BACKGROUND: The carnitine acetyltransferase (CrAT) is a mitochondrial matrix protein that directly influences intramitochondrial acetyl-CoA pools. Murine CrAT is encoded by a single gene located in the opposite orientation head to head to the PPP2R4 gene, sharing a very condensed bi-directional promoter. Since decreased CrAT expression is correlated with metabolic inflexibility and subsequent pathological consequences, our aim was to reveal and define possible activators of CrAT transcription in the normal embryonic murine liver cell line BNL CL. 2 and via which nuclear factors based on key metabolites mainly regulate hepatic expression of CrAT. Here we describe a functional characterization of the CrAT promoter region under conditions of L-carnitine deficiency and supplementation as well as fenofibrate induction in cell culture cells. RESULTS: The murine CrAT promoter displays some characteristics of a housekeeping gene: it lacks a TATA-box, is very GC-rich and harbors two Sp1 binding sites. Analysis of the promoter activity of CrAT by luciferase assays uncovered a L-carnitine sensitive region within -342 bp of the transcription start. Electrophoretic mobility shift and supershift assays proved the sequence element (-228/-222) to be an L-carnitine sensitive RXRα binding site, which also showed sensitivity to application of anti-PPARα and anti-PPARbp antibodies. In addition we analysed this specific RXRα/PPARα site by Southwestern Blotting technique and could pin down three protein factors binding to this promoter element. By qPCR we could quantify the nutrigenomic effect of L-carnitine itself and fenofibrate. CONCLUSIONS: Our results indicate a cooperative interplay of L-carnitine and PPARα in transcriptional regulation of murine CrAT, which is of nutrigenomical relevance. We created experimental proof that the muCrAT gene clearly is a PPARα target. Both L-carnitine and fenofibrate are inducers of CrAT transcripts, but the important hyperlipidemic drug fenofibrate being a more potent one, as a consequence of its pharmacological interaction.
Assuntos
Carnitina O-Acetiltransferase/genética , Carnitina/antagonistas & inibidores , Fenofibrato/farmacologia , Regulação da Expressão Gênica/efeitos dos fármacos , Hepatócitos/efeitos dos fármacos , Hepatócitos/metabolismo , PPAR alfa/antagonistas & inibidores , Regiões 5' não Traduzidas , Animais , Sequência de Bases , Carnitina/metabolismo , Carnitina/farmacologia , Núcleo Celular/metabolismo , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Ordem dos Genes , Camundongos , Dados de Sequência Molecular , PPAR alfa/metabolismo , PPAR alfa/farmacologia , Regiões Promotoras Genéticas , Ligação Proteica , Transporte Proteico , RNA Mensageiro/genéticaRESUMO
γ-Butyrobetaine hydroxylase (BBOX) catalyzes the conversion of gamma butyrobetaine (GBB) to l-carnitine, which is involved in the generation of metabolic energy from long-chain fatty acids. BBOX inhibitor 3-(1,1,1-trimethylhydrazin-1-ium-2-yl)propanoate (mildronate), which is an approved, clinically used cardioprotective drug, is a relatively poor BBOX inhibitor and requires high daily doses. In this paper we describe the design, synthesis, and properties of 51 compounds, which include both GBB and mildronate analogues. We have discovered novel BBOX inhibitors with improved IC50 values; the best examples are in the nanomolar range and about 2 orders of magnitude better when compared to mildronate. For six inhibitors, crystal structures in complex with BBOX have been solved to explain their activities and pave the way for further inhibitor design.
Assuntos
Carnitina/antagonistas & inibidores , Carnitina/biossíntese , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/farmacologia , gama-Butirobetaína Dioxigenase/antagonistas & inibidores , Calorimetria , Cristalografia por Raios X , Desenho de Fármacos , Humanos , Indicadores e Reagentes , Cinética , Ligantes , Espectroscopia de Ressonância Magnética , Metilidrazinas/química , Metilidrazinas/farmacologia , Modelos Moleculares , Conformação Molecular , Ligação Proteica , Proteínas Recombinantes/química , Relação Estrutura-Atividade , gama-Butirobetaína Dioxigenase/genéticaRESUMO
The preservation of mitochondrial function is essential for normal brain function after ischaemia-reperfusion injury. l-carnitine is a cofactor involved in the regulation of cellular energy metabolism. Recently, it has been shown that mildronate, an inhibitor of l-carnitine transport, improves neurological outcome after ischaemic damage of brain tissues. The aim of the present study was to elucidate the mitochondria targeted neuroprotective action of mildronate in the model of anoxia-reoxygenation-induced injury. Wistar rats were treated daily with mildronate (per os; 100mg/kg) for 14 days. The acyl-carnitine profile was determined in the brain tissues. Mitochondrial respiration and the activities of carnitine acetyltransferase (CrAT) and tricarboxylic acid (TCA) cycle enzymes were measured. To assess tolerance to ischaemia, isolated mitochondria were subjected to anoxia followed by reoxygenation. The mildronate treatment significantly reduced the concentrations of free l-carnitine (FC) and short-chain acyl-carnitine (AC) in brain tissue by 40-76%, without affecting the AC:FC ratio. The activities of CrAT and TCA cycle enzymes were slightly increased after mildronate treatment. Despite partially induced uncoupling, mildronate treatment did not affect mitochondrial bioenergetics function under normoxic conditions. After exposure to anoxia-reoxygenation, state 3 respiration and the respiration control ratio were higher in the mildronate-treated group. The results obtained demonstrate that mildronate treatment improves tolerance against anoxia-reoxygenation due to an uncoupling preconditioning-like effect. Regulating l-carnitine availability provides a potential novel target for the treatment of cerebral ischaemia and related complications.
Assuntos
Encéfalo/efeitos dos fármacos , Carnitina/antagonistas & inibidores , Metilidrazinas/farmacologia , Mitocôndrias/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Acil Coenzima A/metabolismo , Trifosfato de Adenosina/metabolismo , Animais , Encéfalo/metabolismo , Carnitina/metabolismo , Carnitina Aciltransferases/metabolismo , Respiração Celular/efeitos dos fármacos , Hipóxia/metabolismo , Masculino , Mitocôndrias/metabolismo , Oxigênio/metabolismo , Ratos , Ratos WistarRESUMO
PURPOSE: Dietary sesamin (1:1 mixture of sesamin and episesamin) decreases fatty acid synthesis but increases fatty acid oxidation in rat liver. Dietary α-lipoic acid lowers hepatic fatty acid synthesis. These changes can account for the serum lipid-lowering effect of sesamin and α-lipoic acid. It is expected that the combination of these compounds in the diet potentially ameliorates lipid metabolism more than the individual compounds. We therefore studied the combined effect of sesamin and α-lipoic acid on lipid metabolism in rats. METHODS: Male Sprague-Dawley rats were fed diets supplemented with 0 or 2 g/kg sesamin and containing 0 or 2.5 g/kg α-lipoic acid for 22 days. RESULTS AND CONCLUSIONS: Sesamin and α-lipoic acid decreased serum lipid concentrations and the combination of these compounds further decreased the parameters in an additive fashion. These compounds reduced the hepatic concentration of triacylglycerol, the lignan being less effective in decreasing this value. The combination failed to cause a stronger decrease in hepatic triacylglycerol concentration. The combination of sesamin and α-lipoic acid decreased the activity and mRNA levels of hepatic lipogenic enzymes in an additive fashion. Sesamin strongly increased the parameters of hepatic fatty acid oxidation enzymes. α-Lipoic acid antagonized the stimulating effect of sesamin of fatty acid oxidation through reductions in the activity of some fatty acid oxidation enzymes and carnitine concentration in the liver. This may account for the failure to observe strong reductions in hepatic triacylglycerol concentration in rats given a diet containing both sesamin and α-lipoic acid.
Assuntos
Suplementos Nutricionais , Dioxóis/administração & dosagem , Regulação Enzimológica da Expressão Gênica , Hipolipemiantes/administração & dosagem , Lignanas/administração & dosagem , Metabolismo dos Lipídeos , Fígado/metabolismo , Ácido Tióctico/administração & dosagem , Animais , Depressores do Apetite/administração & dosagem , Depressores do Apetite/química , Carnitina/antagonistas & inibidores , Carnitina/metabolismo , Dioxóis/antagonistas & inibidores , Ácidos Graxos/sangue , Ácidos Graxos/metabolismo , Hipolipemiantes/antagonistas & inibidores , Lignanas/antagonistas & inibidores , Lipogênese , Lipólise , Fígado/enzimologia , Fígado/crescimento & desenvolvimento , Masculino , Tamanho do Órgão , RNA Mensageiro/metabolismo , Ratos , Ratos Sprague-Dawley , Ácido Tióctico/antagonistas & inibidores , Triglicerídeos/sangue , Triglicerídeos/metabolismo , Aumento de PesoRESUMO
BACKGROUND: In newborn screening with tandem mass spectrometry, multiple intermediary metabolites are quantified in a single analytical run for the diagnosis of fatty-acid oxidation disorders, organic acidurias, and aminoacidurias. Published diagnostic criteria for these disorders normally incorporate a primary metabolic marker combined with secondary markers, often analyte ratios, for which the markers have been chosen to reflect metabolic pathway deviations. METHODS: We applied a procedure to extract new markers and diagnostic criteria for newborn screening to the data of newborns with confirmed medium-chain acyl-CoA dehydrogenase deficiency (MCADD) and a control group from the newborn screening program, Heidelberg, Germany. We validated the results with external data of the screening center in Hamburg, Germany. We extracted new markers by performing a systematic search for analyte combinations (features) with high discriminatory performance for MCADD. To select feature thresholds, we applied automated procedures to separate controls and cases on the basis of the feature values. Finally, we built classifiers from these new markers to serve as diagnostic criteria in screening for MCADD. RESULTS: On the basis of chi(2) scores, we identified approximately 800 of >628,000 new analyte combinations with superior discriminatory performance compared with the best published combinations. Classifiers built with the new features achieved diagnostic sensitivities and specificities approaching 100%. CONCLUSION: Feature construction methods provide ways to disclose information hidden in the set of measured analytes. Other diagnostic tasks based on high-dimensional metabolic data might also profit from this approach.
Assuntos
Acil-CoA Desidrogenase/deficiência , Erros Inatos do Metabolismo/diagnóstico , Triagem Neonatal/métodos , Algoritmos , Inteligência Artificial , Biomarcadores/sangue , Carnitina/antagonistas & inibidores , Carnitina/sangue , Humanos , Recém-Nascido , Erros Inatos do Metabolismo/classificação , Espectrometria de Massas por Ionização por Electrospray , Espectrometria de Massas em TandemRESUMO
The inhibition of gamma-butyrobetaine (GBB) hydroxylase, a key enzyme in the biosynthesis of carnitine, contributes to lay ground for the cardioprotective mechanism of action of mildronate. By inhibiting the biosynthesis of carnitine, mildronate is supposed to induce the accumulation of GBB, a substrate of GBB hydroxylase. This study describes the changes in content of carnitine and GBB in rat plasma and heart tissues during long-term (28 days) treatment of mildronate [i.p. (intraperitoneal) 100 mg/kg/daily]. Obtained data show that in concert with a decrease in carnitine concentration, the administration of mildronate caused a significant increase in GBB concentration. We detected about a 5-fold increase in GBB contents in the plasma and brain and a 7-fold increase in the heart. In addition, we tested the cardioprotective effect of mildronate in isolated rat heart infarction model after 3, 7, and 14 days of administration. We found a statistically significant decrease in necrotic area of infarcted rat hearts after 14 days of treatment with mildronate. The cardioprotective effect of mildronate correlated with an increase in GBB contents. In conclusion, our study, for the first time, provides experimental evidence that the long-term administration of mildronate not only decreases free carnitine concentration, but also causes a significant increase in GBB concentration, which correlates with the cardioprotection of mildronate.
Assuntos
Betaína/análogos & derivados , Carnitina/biossíntese , Metilidrazinas/farmacologia , Infarto do Miocárdio/tratamento farmacológico , Animais , Betaína/sangue , Betaína/metabolismo , Fármacos Cardiovasculares/administração & dosagem , Fármacos Cardiovasculares/farmacologia , Carnitina/antagonistas & inibidores , Carnitina/sangue , Carnitina/metabolismo , Cromatografia Líquida de Alta Pressão , Circulação Coronária/efeitos dos fármacos , Técnicas In Vitro , Injeções Intraperitoneais , Masculino , Metilidrazinas/administração & dosagem , Infarto do Miocárdio/sangue , Infarto do Miocárdio/metabolismo , Miocárdio/química , Miocárdio/metabolismo , Miocárdio/patologia , Ratos , Ratos Wistar , gama-Butirobetaína Dioxigenase/antagonistas & inibidores , gama-Butirobetaína Dioxigenase/metabolismoRESUMO
Mildronate [3-(2,2,2-trimethylhydrazine) propionate (THP)] is an antiischemic drug acting mainly via inhibition of fatty acid beta-oxidation. Some effects of the drug cannot be explained by the latter mechanism. We tested the eventual nitric oxide (NO) dependence of the mildronate action. Mildronate, gamma-butyrobetaine (GBB) and GBB methyl ester induced transient increases in nitric oxide (NO) concentrations in rat blood and myocardium. In vitro, these compounds neither modified the activities of purified neuronal and endothelial recombinant nitric oxide synthases (NOSs) nor were able to interact with their active site. GBB induced vasodilatation at high concentrations only (EC50 = 5 x 10(-5) M) while mildronate alone displayed no vasodilating effect although it enhanced the GBB vasodilating activity. GBB methyl and ethyl esters were found more potent vasodilators (EC50 = 2.5 x 10(-6) M). Pretreatment of aortic rings with NOS inhibitor Nomega-nitro-L-arginine methyl ester (L-NAME) abolished vasodilating effects of the compounds. A hypothesis explaining NO and endothelium-dependent effects of mildronate and its analogues is proposed.
Assuntos
Betaína/análogos & derivados , Betaína/farmacologia , Carnitina/farmacologia , Endotélio/fisiologia , Metilidrazinas/uso terapêutico , Óxido Nítrico/fisiologia , Vasodilatação/fisiologia , Animais , Aorta Torácica/efeitos dos fármacos , Aorta Torácica/metabolismo , Betaína/antagonistas & inibidores , Betaína/classificação , Carnitina/antagonistas & inibidores , Carnitina/classificação , Ditiocarb/farmacologia , Combinação de Medicamentos , Avaliação Pré-Clínica de Medicamentos , Sinergismo Farmacológico , Espectroscopia de Ressonância de Spin Eletrônica/métodos , Endotélio/efeitos dos fármacos , Masculino , Metilidrazinas/antagonistas & inibidores , Metilidrazinas/farmacologia , Músculo Liso Vascular/efeitos dos fármacos , Músculo Liso Vascular/fisiologia , Isquemia Miocárdica/tratamento farmacológico , Isquemia Miocárdica/prevenção & controle , NG-Nitroarginina Metil Éster/farmacologia , Óxido Nítrico/antagonistas & inibidores , Óxido Nítrico Sintase/efeitos dos fármacos , Óxido Nítrico Sintase/genética , Óxido Nítrico Sintase/metabolismo , Óxido Nítrico Sintase Tipo III , Ratos , Ratos Wistar , Vasodilatação/efeitos dos fármacosRESUMO
PURPOSE: To examine the inhibitory effect of anticonvulsants (AEDs) on carnitine transport by the human placental carnitine transporter. METHODS: Uptake of radiolabeled carnitine by human placental brush-border membrane vesicles was measured in the absence and presence of tiagabine (TGB), vigabatrin (VGB), gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), valproic acid (VPA), and phenytoin (PHT). The mechanism of the inhibitory action of TGB was determined. RESULTS: Most of the AEDs inhibited placental carnitine transport. Kinetic analyses showed that TGB had the greatest inhibitory effect [50% inhibitory concentration (IC50, 190 microM)], and the order of inhibitory potency was TGB > PHT > GBP > VPA > VGB, TPM > LTG. Further studies showed that TGB competitively inhibited carnitine uptake by the human placental carnitine transporter, suggesting that it may be a substrate for this carrier. CONCLUSIONS: Although the involvement of carnitine deficiency in fetal anticonvulsant syndrome requires further evaluation, potential interference with placental carnitine transport by several AEDs was demonstrated. Despite the higher inhibitory potency of TGB, given the therapeutic unbound concentrations, the results for VPA and PHT are probably more clinically significant.
Assuntos
Aminas , Anticonvulsivantes/efeitos adversos , Anticonvulsivantes/farmacocinética , Carnitina/antagonistas & inibidores , Proteínas de Transporte/metabolismo , Ácidos Cicloexanocarboxílicos , Epilepsia/tratamento farmacológico , Frutose/análogos & derivados , Proteínas de Transporte de Cátions Orgânicos , Placenta/efeitos dos fármacos , Placenta/metabolismo , Complicações na Gravidez/tratamento farmacológico , Ácido gama-Aminobutírico , Acetatos/administração & dosagem , Acetatos/efeitos adversos , Acetatos/farmacocinética , Ácidos Aminoisobutíricos/metabolismo , Anticonvulsivantes/classificação , Carnitina/metabolismo , Técnicas de Cultura , Relação Dose-Resposta a Droga , Esquema de Medicação , Epilepsia/metabolismo , Feminino , Frutose/administração & dosagem , Frutose/efeitos adversos , Frutose/farmacocinética , Gabapentina , Humanos , Lamotrigina , Modelos Biológicos , Ácidos Nipecóticos/administração & dosagem , Ácidos Nipecóticos/efeitos adversos , Ácidos Nipecóticos/farmacocinética , Fenitoína/administração & dosagem , Fenitoína/efeitos adversos , Fenitoína/farmacocinética , Placenta/citologia , Gravidez , Complicações na Gravidez/metabolismo , Proteínas da Gravidez/metabolismo , Membro 5 da Família 22 de Carreadores de Soluto , Tiagabina , Topiramato , Triazinas/administração & dosagem , Triazinas/efeitos adversos , Triazinas/farmacocinética , Ácido Valproico/administração & dosagem , Ácido Valproico/efeitos adversos , Ácido Valproico/farmacocinética , Vigabatrina/administração & dosagem , Vigabatrina/efeitos adversos , Vigabatrina/farmacocinéticaRESUMO
We investigated the contribution of the Na(+)/L-carnitine cotransporter in the transport of tetraethylammonium (TEA) by rat renal brush-border membrane vesicles. The transient uphill transport of L-carnitine was observed in the presence of a Na(+) gradient. The uptake of L-carnitine was of high affinity (K(m)=21 microM) and pH dependent. Various compounds such as TEA, cephaloridine, and p-chloromercuribenzene sulfonate (PCMBS) had potent inhibitory effects for L-carnitine uptake. Therefore, we confirmed the Na(+)/L-carnitine cotransport activity in rat renal brush-border membranes. Levofloxacin and PCMBS showed different inhibitory effects for TEA and L-carnitine uptake. The presence of an outward H(+) gradient induced a marked stimulation of TEA uptake, whereas it induced no stimulation of L-carnitine uptake. Furthermore, unlabeled TEA preloaded in the vesicles markedly enhanced [14C]TEA uptake, but unlabeled L-carnitine did not stimulate [14C]TEA uptake. These results suggest that transport of TEA across brush-border membranes is independent of the Na(+)/L-carnitine cotransport activity, and organic cation secretion across brush-border membranes is predominantly mediated by the H(+)/organic cation antiporter.
Assuntos
Carnitina/metabolismo , Rim/metabolismo , Proteínas de Transporte de Cátions Orgânicos/metabolismo , Tetraetilamônio/metabolismo , 4-Cloromercuriobenzenossulfonato/farmacologia , Animais , Transporte Biológico Ativo , Carnitina/antagonistas & inibidores , Concentração de Íons de Hidrogênio , Levofloxacino , Masculino , Microvilosidades/metabolismo , Ofloxacino/farmacologia , Ratos , Ratos Wistar , Reagentes de Sulfidrila/farmacologia , Tetraetilamônio/antagonistas & inibidoresRESUMO
The AGP2 gene encodes a plasma membrane carnitine transporter in S. cerevisiae. Here, we report the identification of AGP2 as an osmotic stress response gene. AGP2 was isolated from mTn3 tagged mutants that contained in-frame fusions with lacZ. The expression of AGP2 was down-regulated by osmotic stresses, including NaCl, sorbitol, and KCI. We also found that carnitine uptake was inhibited by NaCl. In the ssk1delta stelldelta double-mutant strain, the expression of AGP2 and the uptake of carnitine were greatly reduced compared to the wild-type strain. Furthermore, carnitine uptake was inhibited by the constitutive expression of PBS2, which encodes a MAPKK that activates Hog1. We concluded, therefore, that the HOG pathway plays an important role in the regulation of carnitine uptake in S. cerevisiae.
Assuntos
Sistemas de Transporte de Aminoácidos/metabolismo , Carnitina/antagonistas & inibidores , Carnitina/farmacocinética , Proteínas Quinases Ativadas por Mitógeno/fisiologia , Proteínas de Saccharomyces cerevisiae/metabolismo , Proteínas de Saccharomyces cerevisiae/fisiologia , Saccharomyces cerevisiae/metabolismo , Simportadores/metabolismo , Sistemas de Transporte de Aminoácidos/antagonistas & inibidores , Sistemas de Transporte de Aminoácidos/genética , Sistemas de Transporte de Aminoácidos/isolamento & purificação , Regulação para Baixo/efeitos dos fármacos , Quinases de Proteína Quinase Ativadas por Mitógeno/farmacologia , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Mutação , Proteínas de Saccharomyces cerevisiae/antagonistas & inibidores , Proteínas de Saccharomyces cerevisiae/genética , Proteínas de Saccharomyces cerevisiae/isolamento & purificação , Cloreto de Sódio/farmacologia , Simportadores/antagonistas & inibidores , Simportadores/genética , Simportadores/isolamento & purificaçãoRESUMO
It was previously reported that inhibition of carnitine synthesis by 3-(2,2,2-trimethyl-hydrazinium) propionate (MET-88) restores left ventricular (LV) systolic and diastolic function in rats with myocardial infarction (MI). Preservation of the calcium uptake function of sarcoplasmic reticulum Ca2+-ATPase (SERCA2) is one of the possible mechanisms by which MET-88 alleviates hemodynamic dysfunction. To test this hypothesis, the effects of MET-88 on protein content of SERCA2 were evaluated using the same rat model of heart failure. Myocardial protein content of hexokinase, which is one of the key enzymes of glucose utilization, was also measured. Either MET-88 (MET-88 group) or a placebo (MI group) was administered for 20 days to rats with MI induced by coronary artery ligation. The control group underwent sham surgery (no ligation) and received placebo. In LV myocardial homogenates, the myocardial SERCA2 protein content was 32% lower (p<0.05) in the MI group than in the control group. However, in the MET-88 group myocardial SERCA2 content was the same as in the control group. Hexokinase I protein content was 29 % lower (p<0.05) in the MI group compared with the control. In contrast, hexokinase II protein content did not differ significantly among the three groups. Consequently, inhibition of carnitine synthesis ameliorates depression of SERCA2 and hexokinase I protein content which may reduce tissue damage caused by MI.
Assuntos
ATPases Transportadoras de Cálcio/metabolismo , Carnitina/antagonistas & inibidores , Hexoquinase/metabolismo , Isoenzimas/metabolismo , Infarto do Miocárdio/metabolismo , Miocárdio/enzimologia , Animais , Fármacos Cardiovasculares/farmacologia , Carnitina/biossíntese , Masculino , Metilidrazinas/farmacologia , Ratos , Ratos Sprague-Dawley , ATPases Transportadoras de Cálcio do Retículo SarcoplasmáticoRESUMO
L-Carnitine facilitates the transport of fatty acids into the mitochondrial matrix where they are used for energy production. Recent studies have shown that L-carnitine is capable of protecting the heart against ischemia/reperfusion injury and has beneficial effects against Alzheimer's disease and AIDS. The mechanism of action, however, is not yet understood. In the present study, we found that in Jurkat cells, L-carnitine inhibited apoptosis induced by Fas ligation. In addition, 5 mM carnitine potently inhibited the activity of recombinant caspases 3, 7 and 8, whereas its long-chain fatty acid derivative palmitoylcarnitine stimulated the activity of all the caspases. Palmitoylcarnitine reversed the inhibition mediated by carnitine. Levels of carnitine and palmitoyl-CoA decreased significantly during Fas-mediated apoptosis, while palmitoylcarnitine formation increased. These alterations may be due to inactivation of beta-oxidation or to an increase in the activity of the enzyme that converts carnitine to palmitoylcarnitine, carnitine palmitoyltransferase I (CPT I). In support of the latter possibility, fibroblasts deficient in CPT I activity were relatively resistant to staurosporine-induced apoptosis. These observations suggest that caspase activity may be regulated in part by the balance of carnitine and palmitoylcarnitine.
Assuntos
Apoptose/efeitos dos fármacos , Carnitina/farmacologia , Caspases/metabolismo , Palmitoilcarnitina/farmacologia , Receptor fas/fisiologia , Acilação , Carnitina/análogos & derivados , Carnitina/antagonistas & inibidores , Carnitina/metabolismo , Carnitina O-Palmitoiltransferase/deficiência , Carnitina O-Palmitoiltransferase/genética , Carnitina O-Palmitoiltransferase/metabolismo , Caspase 3 , Caspase 7 , Caspase 8 , Caspase 9 , Inibidores de Caspase , Linhagem Celular , Relação Dose-Resposta a Droga , Ativação Enzimática/efeitos dos fármacos , Fibroblastos , Humanos , Células Jurkat , Palmitoil Coenzima A/metabolismo , Palmitoilcarnitina/antagonistas & inibidores , Palmitoilcarnitina/metabolismo , Estaurosporina/farmacologiaRESUMO
Therapeutic use of cephaloridine, a beta-lactam antibiotic, in humans is associated with carnitine deficiency. A potential mechanism for the development of carnitine deficiency is competition between cephaloridine and carnitine for the renal reabsorptive process. OCTN2 is an organic cation/carnitine transporter that is responsible for Na(+)-coupled transport of carnitine in the kidney and other tissues. We investigated the interaction of several beta-lactam antibiotics with OCTN2 using human cell lines that express the transporter constitutively as well as using cloned human and rat OCTN2s expressed heterologously in human cell lines. The beta-lactam antibiotics cephaloridine, cefoselis, cefepime, and cefluprenam were found to inhibit OCTN2-mediated carnitine transport. These antibiotics possess a quaternary nitrogen as does carnitine. Several other beta-lactam antibiotics that do not possess this structural feature did not interact with OCTN2. The interaction of cephaloridine with OCTN2 is competitive with respect to carnitine. Interestingly, many of the beta-lactam antibiotics that were not recognized by OCTN2 were good substrates for the H(+)-coupled peptide transporters PEPT1 and PEPT2. In contrast, cephaloridine, cefoselis, cefepime, and cefluprenam, which were recognized by OCTN2, did not interact with PEPT1 and PEPT2. The interaction of cephaloridine with OCTN2 was Na(+)-dependent, whereas the interaction of cefoselis and cefepime with OCTN2 was largely Na(+)-independent. Furthermore, the Na(+)-dependent, OCTN2-mediated cellular uptake of cephaloridine could be demonstrated by direct uptake measurements. These studies show that OCTN2 plays a crucial role in the pharmacokinetics and therapeutic efficacy of certain beta-lactam antibiotics such as cephaloridine and that cephaloridine-induced carnitine deficiency is likely to be due to inhibition of carnitine reabsorption in the kidney.
Assuntos
Antibacterianos/metabolismo , Carnitina/farmacocinética , Proteínas de Transporte/metabolismo , Proteínas de Membrana/metabolismo , Proteínas de Transporte de Cátions Orgânicos , Acetilcarnitina/farmacocinética , Animais , Carnitina/análogos & derivados , Carnitina/antagonistas & inibidores , Cefadroxila/farmacologia , Cefepima , Cefaloridina/farmacocinética , Cefalosporinas/química , Cefalosporinas/farmacocinética , Relação Dose-Resposta a Droga , Células HeLa , Humanos , Cinética , Nitrogênio/metabolismo , Ratos , Sódio/metabolismo , Membro 5 da Família 22 de Carreadores de Soluto , Células Tumorais CultivadasRESUMO
Results from recent animal models with implications for putative human male contraceptives acting on the epididymis are reviewed. Inducing sterility by enhancing sperm transport through the epididymis has not been achieved. The induction of infertility in males of several species is easier to achieve by direct actions of drugs on sperm function (e.g. inhibition of sperm-specific isoenzymes of the glycolytic pathway by chloro-compounds) than by indirectly reducing amounts of epididymal secretions normally present in high concentration (e.g. alpha-glucosidase, L-carnitine). The former show promise for the clinic since human spermatozoa are susceptible to inhibition. On the other hand, the infertile male mice of the c-ros knock-out model demonstrate the influence of even a small region of the epididymis on fertility, so that targeting the as yet unknown epididymal factors presumably secreted in limiting amounts by this epididymal segment, is a new lead for a contraceptive. Targeting a specific sperm protein acquired in the testis, but depleted in the epididymis by toxicants that induce rapid infertility, may also lead to the discovery of new contraceptives, but these will require developing new means of organ-specific delivery of contraceptive drugs.
Assuntos
Anticoncepcionais Masculinos/farmacologia , Epididimo/efeitos dos fármacos , Espermatogênese/fisiologia , Espermatozoides/efeitos dos fármacos , Animais , Carnitina/antagonistas & inibidores , Carnitina/fisiologia , Epididimo/metabolismo , Feminino , Glucosidases/antagonistas & inibidores , Glucosidases/efeitos dos fármacos , Glucosidases/fisiologia , Humanos , Masculino , Camundongos , Camundongos Knockout , Ornidazol/farmacologia , Gravidez , Espermatozoides/fisiologiaRESUMO
The induction of infertility in males of several species through epididymal interference is more difficult to achieve by reduction of the amounts of epididymal secretions (eg alpha-glucosidase, L-carnitine) or immunological interference with secreted proteins (eg D/E, P34H, P26h) than by direct actions of drugs on sperm function (eg inhibition of glyceraldehyde 3-phosphate dehydrogenase by chloro-compounds). The latter approach holds promise for mankind as human sperm are susceptible to glycolytic inhibition. Future contraceptive developments may arise from production of targeted inhibitors, research on the displacement of sperm proteins in the epididymis and interference with sperm plasma membrane ion channels.
Assuntos
Anticoncepcionais Masculinos , Epididimo , Animais , Carnitina/antagonistas & inibidores , Anticoncepcionais Masculinos/imunologia , Epitélio , Glicólise , Inibidores de Glicosídeo Hidrolases , Humanos , Canais Iônicos/antagonistas & inibidores , Masculino , Espermatozoides/efeitos dos fármacos , Espermatozoides/metabolismo , TestículoRESUMO
3-(2,2,2-trimethylhydrazinium) propionate (MET-88) is an inhibitor of carnitine synthesis. This study was carried out to investigate whether or not reduction of carnitine content could attenuate hypoxic damage in isolated perfused rat hearts. Rats were divided into four groups: 1) vehicle control; 2) pretreatment with MET-88 (MET-88); 3) application of insulin (500 muU/mL) in the perfusate (insulin); and 4) pretreatment with MET-88 and application of insulin (MET-88 + insulin). MET-88 (100 mg/kg) was orally administered once a day for 10 days until the day before the experiments. Hearts were initially perfused for a 10 min period under normoxia, followed by a 30 min period under hypoxia. Hearts were frozen at the end of hypoxia for the measurement of high-energy phosphates, carnitine derivatives, and glycolysis intermediates. In a separate series of untreated and MET-88 treated hearts, exogenous glucose and palmitate oxidation was measured. MET-88 decreased the extent of the depression of cardiac contractility (+dP/dt), and aortic flow during the hypoxic state. Insulin also improved cardiac function, and co-treatment of MET-88 and insulin additionally improved cardiac function during hypoxia. MET-88 prevented the decrease of high-energy phosphate and the increase of long-chain acylcarnitine after 30 min of hypoxic perfusion. In addition, MET-88 increased the steady state of glucose oxidation in hypoxic perfused rat hearts. These results indicate that MET-88 has cardioprotective effects on contractile function and energy metabolism of isolated perfused rat hearts in a hypoxic condition. Preventing the accumulation of long-chain acylcarnitine may serve to protect hypoxic hearts.